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Abstract
Ku70 was first characterized as a nuclear factor that binds DNA double-strand breaks in nonhomolog end-joining
DNA repair. However, recent studies have shown that Ku70 is also found in the cytoplasm and binds Bax, preventing
Bax-induced cell death. We have shown that, in neuroblastoma cells, the binding between Ku70 and Bax depends
on the acetylation status of Ku70, such that, when Ku70 is acetylated, Bax is released from Ku70, triggering cell
death. Thus, to survive, in neuroblastoma cells, cytoplasmic Ku70 acetylation status is carefully regulated such that
Ku70 is maintained in a deacetylated state, keeping Bax complexed with Ku70. We have shown that overexpression
of CREB-binding protein (CBP), a known acetyltransferase that acetylates Ku70, releases Bax from Ku70, triggering
apoptosis. Although we have shown that blocking deacetylase activity using non–type-specific inhibitors also trig-
gers Ku70 acetylation and Bax-dependent cell death, the targets of these deacetylase inhibitors in neuroblastoma
cells remain unknown. Here, we demonstrate that, in neuroblastoma cells, histone deacetylase 6 (HDAC6) binds
Ku70 and Bax in the cytoplasm and that knocking down HDAC6 or using an HDAC6-specific inhibitor triggers Bax-
dependent cell death. Our results show that HDAC6 regulates the interaction between Ku70 and Bax in neuroblastoma
cells and may be a therapeutic target in this pediatric solid tumor.
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Introduction
Neuroblastoma (NB) is a cancer diagnosed in infants and children. It
develops during embryogenesis and after birth from sympathoadrenal
stem cells in the adrenal gland or paraspinal locations [1]. Compared
with most other childhood cancers, NB is difficult to cure; half of the
cases are classified as high risk of relapse, and for these patients, the
best available treatment results in a survival rate of less than 40% [2].
Current treatment regimens are dose-intense, involve cytotoxic drugs,
and pose significant risks of serious short-term and long-term mor-
bidity [3].
To identify new pharmacological targets in NB, we have recently
described a novel pharmacologic approach to unleash cytosolic Bax
and trigger apoptosis by inhibiting histone deacetylases (HDACs) in
NB cells [4,5]. HDACs regulate the function of histones and many
nonhistone proteins by modulating their acetylation status [6]. The
HDAC family of proteins is divided into two categories: zinc-dependent
enzymes (HDAC1-11) and NAD+-dependent enzymes (SIRT1-7) [7].
The zinc-dependent HDACs are subdivided into two classes: class 1
and class 2. HDAC inhibitors (HDACIs) are a new class of anticancer
compounds [8]. Trichostatin A (TSA) and vorinostat (SAHA), class 1
and class 2 HDAC inhibitors, have promising antitumor effects against
NB in preclinical models [9].
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Our model is that Bax activation is central to the mechanism by
which HDACI work against NB. The expression of the proapoptotic
cytosolic protein Bax is high in NB cells and is linked to unfavorable
outcomes. It has been hypothesized that, as a survival mechanism of
NB tumor cells, Bax-dependent apoptosis is suppressed, particularly
in advanced stage disease where increased expression is linked to unfa-
vorable outcomes [10]. Elevated levels of the antiapoptotic proteins
Bcl-2 and Bcl-xL, which work by inhibiting Bax, are correlated with
poor prognosis, MYCN amplification, and chemotherapy resistance
[11,12]. Caspase 8, which normally activates Bax in response to extra-
cellular death signals, is epigenetically silenced in poor prognosis dis-
ease, effectively reducing Bax activation [13,14]. These two common
motifs of high-risk NB tumors, namely, high levels of Bax protein
and failure of Bax activation, led us to hypothesize that Bax activation
is restrained in NB and that exploiting mechanisms that release the
restraints on Bax could have antitumor effects.
Our results have shown that HDAC inhibition causes Bax-induced
cell death by increasing acetylation of cytosolic Ku70, a multifunc-
tional nuclear and cytosolic protein best known for its role in the nu-
cleus as a factor in DNA repair [15]. Cytosolic deacetylated Ku70
sequesters activated Bax and suppresses apoptosis [16]. When Ku70
is acetylated, it loses its ability to bind Bax. In tumorigenic neuro-
blastic cell models of NB, we showed that Ku70 acetylation is in-
creased by HDACI treatment, disrupting Ku70 binding to Bax,
thereby causing activated Bax to translocate from the cytosol to the
mitochondria and triggering cell death [5]. NB cells are poised to un-
dergo spontaneous cell death when Ku70-Bax binding is disrupted. In-
deed, our studies have shown that Ku70 acetylation is necessary for
HDACIs to kill tumorigenic neuroblastic-type (N-type) NB cells
[4,5]. Non–NB-cell types tested do not require Ku70-Bax binding
for survival (data not shown); therefore, treatments designed to disrupt
Ku70-Bax have the potential to be selective on the basis of both Ku70
deacetylation and Ku70-Bax binding. Interestingly, nontumorigenic
stromal-type (S-type) NB cells that fail to acetylate Ku70 in response
to HDACIs are likewise resistant to these agents.
Although we and others have demonstrated that the CREB-binding
protein (CBP) acetylates Ku70, the deacetylase(s) that deacetylates
Ku70 in NB cells is unknown. Here, we provide experimental evi-
dence demonstrating that tubulin deacetylase, HDAC6, associates
with Ku70 in NB cells and that knocking down HDAC6 or using
an HDAC6-specific inhibitor, tubacin, induces Ku70 acetylation,
Bax release, and NB-cell death. These results are critical to establish
which protein targets should be evaluated in studies designed to de-
termine protein expression of relevant HDACs in NB tumors. These
results will also guide development of type-specific HDAC inhibitors
for use in NB.
Materials and Methods
Cell Culture and Cell Transfection
Human NB cell lines SH-EP1, SH-SY5Y, IMR32, and SK-N-AS
were cultured in modified Eagle medium supplemented with 10% fetal
bovine serum, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin and maintained at 37°C in a humidified 5% CO2 incu-
bator. IMR32 medium was further supplemented with 1 mM pyruvate
and 0.075% NaHCO3. SH-SY5Y cells were transiently transfected for
immunoprecipitation with either wild-type pCMV-2B-Ku70-FLAG or
mutant pCMV-2B Ku70 K539R/K542R using Nucleofector Kit V
(Amexa, Lonza, Basel, Switzerland) as per the manufacturer’s protocol
[4]. SH-EP1 cells expressing stable full-length pCDNA3-HDAC6-FLAG
Figure 1. Class I and II HDACs are expressed in N-type and S-type NB-cell lines. (A) Cell lysates from two N-type (IMR32 and SH-SY5Y)
and two S-type (SH-EP1 and SK-N-AS) NB lines were blotted for class I HDACs (HDACs 1, 2, and 3) and class II HDACs (HDACs 4, 6, and 7).
As a loading control, the same blot was stripped and reprobed for β-tubulin. (B) Densitometry scans for immunoblots shown in A. Results
are expressed as a relative ratio to β-tubulin, and each bar presents the mean of three experiments.
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protein or the empty vector were generated by cotransfecting the cells
with vector and puromycin expression vector or full-length HDAC6
and puromycin expression vector. A clonal population expressing high
levels of HDAC6 was obtained using puromycin selection (1 μg/ml).
Cell Viability Assay
N-type SH-SY5Y and S-type SH-EP1 human NB-cell lines were
treated with varying concentrations of MS275, tubacin, and SAHA,
and viability was determined after 24 and 48 hours by MTT assay as
previously described [17]. All experiments were carried out three times
with triplicates in each experiment, and means and SDs were calculated.
Trypan blue exclusion assay was used to determine the viability of
cells shown in Figures 3, 4, and 5. Two-tailed t test was used to deter-
mine the statistical significance between treated and control samples,
*P ≤ .05 (n = 3).
Small Interfering RNA–Mediated Silencing
SH-SY5Y cells and SH-EP1 cells were plated at a density of ∼2 ×
106 cells per 10-cm plate 24 hours before transfection. The following
day, the cells were transfected either with smart pool HDAC6 small
interfering RNA (siRNA) or HDAC1 siRNA or HDAC2 siRNA or
HDAC3 siRNA or the scrambled nontargeting siRNA (Dharmacon,
Inc, Chicago, IL) using Nucleofector Kit V (Amexa) as per the manufac-
turer’s instruction. Mock transfection as well as the nontargeting siRNA
transfection served as controls. The knockdowns of HDACs were mea-
sured 72 hours after transfection by immunoblot analysis using HDAC
antibodies. The viability of cells after knockdown was measured by
counting cells using trypan blue exclusion analysis.
Western Blot Analysis
For the immunoblot analysis, whole-cell extracts were prepared as de-
scribed [4] from SH-SY5Y, SH-EP1, IMR32, or SK-N-AS humanNB-cell
lines. Proteins were separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to poly(vinylidene fluoride)
membranes, and then blotted for different HDACs. The following anti-
bodies were used for Western blot analyses: CBP (A-22), Ku70 (A-9),
HDAC1 (H-51), HDAC2 (H-54), HDAC3 (H-99), HDAC7 (H-273),
and HDAC8 (E-5) from Santa Cruz Biotechnology (Santa Cruz, CA);
Flag (F-1804) and β-tubulin (T-4026) from Sigma (St Louis, MO);
Bax NT (06-499) from Upstate (Millipore, Billerica, MA); HDAC6
Figure 2. N-type (SH-SY5Y) and not S-type (SH-EP1) NB cells are sensitive to tubacin, an HDAC6-specific inhibitor. Cells are treated with
various concentrations of a pan-HDAC inhibitor (SAHA), class I–specific HDAC inhibitor (MS275), or HDAC6-specific inhibitor (tubacin).
The viability of the cells was assessed by MTT assay at 24 and 48 hours. Results are expressed as the percentage of viable cells com-
pared with vehicle control (mean ± SD, n = 3). All 48-hour data points were significant from controls. The P values for all 48-hour data
points were as follows: for SH-SY5Y cells, tubacin = .003, MS275 = .003, SAHA = .001; for SH-EP1 cells, tubacin = .005, MS275 = .002,
SAHA = .0007.
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(A-4006) from Epigentek (Farmingdale, NY); and HDAC4 (2072)
and acetylated lysine (Ac-K-103) from Cell Signaling (Danvers, MA).
The presence of protein was visualized by using Enhanced Chemi-
luminescence Plus (GE Healthcare, Piscataway, NJ).
Immunoprecipitation
Coimmunoprecipitation of Bax and Ku70 from SH-SY5Y and
SH-EP1 cells was performed in CHAPS buffer according to the protocol
described by Sawada et al. [18]. Immunoprecipitation of endogenous Bax
before and after tubacin treatment for Ku70 wild-type– and mutant-
transfected SH-SY5Y cells as well as immunoprecipitation with acetylated
lysine antibody with and without TSA or tubacin treatment in SH-SY5Y
cells was also performed using the above-mentioned protocol.
Immunohistochemistry on NB Tumors
HDAC6 expression in primary neuroblastic tumors was assessed
by immunohistochemical staining of previously described tissue mi-
croarrays [4]. Briefly, these arrays are composed of triplicate samples
of 1.0-mm cores taken from 48 paraffin-embedded, formalin-fixed
neuroblastic tumors (32 NBs, 10 intermixed and nodular ganglio-
neuroblastomas, and 6 ganglioneuromas) and 5 normal adrenal
glands. Immunohistochemistry was performed using a commercially
available polyclonal antibody (no. A4006; Epigentek) according to
the manufacturer’s recommended protocol at a 1:200 dilution using
manual methods. Signals were evaluated for tumoral distribution
(neuroblastic cells vs Schwann stromal cells), cellular distribution
(nuclear vs cytoplasmic), and intensity (semiquantitatively graded as
0, 1+, 2+, or 3+). For each evaluated specimen, the mean neuroblastic
component staining, the mean stromal component staining, and the
mean component staining difference were calculated for all three cores.
Results
Knocking Down or Inhibiting HDAC6 Induces Cell Death
in NB Cells
Our recent studies have shown that a non–type-specific HDACI,
TSA, inhibits HDAC activity and induces cell death in N-type NB
cells but not in S-type cells. Because TSA inhibits both class 1 and
class 2 HDACs, to identify specific HDACs that deacetylate Ku70,
we first determined whether there are any notable differences be-
tween class 1 and class 2 HDACs in NB cells. We determined the
level of three class 1 HDACs (1, 2, and 3) and three class 2 HDACs
Figure 3. Knocking down HDAC6, not class I HDACs, kills N-type NB cells. (A) SH-SY5Y cells were transfected with scrambled siRNA
or HDAC6-specific siRNA. Cell lysates were prepared 48 hours after transfection and then blotted for HDAC6 and HDAC1, 2, 3, 4, 7, or 8.
β-Tubulin was used as a loading control. (B) Cell viability after knockdown of HDAC6 was measured by trypan blue exclusion assay.
Results are expressed as mean ± SD percent of control, n = 3. The P value of the significant difference between HDAC6-specific siRNA
sample and the scrambled siRNA sample was .0006. (C) SH-SY5Y cells were transfected with scrambled siRNA, siRNA against HDAC1, 2,
or 3. A mock transfection was used as a control. Cell lysates were prepared 48 hours after transfection and then blotted for HDAC1, 2, or
3. β-Tubulin was used as a loading control. (D) Cell viability wasmeasured by trypan blue exclusion assay after HDAC1, 2, or 3 knockdown.
Results are expressed as mean ± SD percent of control, n = 3.
Neoplasia Vol. 13, No. 8, 2011 HDAC6 and Ku70-Bax in NB Subramanian et al. 729
(4, 6, 7) in twoN-type NB cells (IMR-32 and SH-SY5Y) and two S-type
NB cells (SH-EP1 and SK-N-AS). Figure 1A shows the immuno-
blots for all HDACs determined, and Figure 1B shows the densito-
metric scans of the results shown in Figure 1A. These results were
normalized with β-tubulin as a loading control. These results indi-
cate that there are no large differences among all except that there is
a higher expression of HDAC1 in IMR32, one of two N-type NB
cells, and that HDAC6 level in SH-EP1 cells is the lowest of all cell
lines tested.
Next, we sought to use type-specific inhibitors to determine the
HDACs involved in TSA-induced killing. Although there are many
experimental type-specific HDACI, few are commercially available.
The most common HDACIs available are MS275, which specifi-
cally inhibits HDACs 1, 2, and 3; and tubacin, an HDAC6 inhibitor.
We used SAHA in these experiments as a control because it is in the
same class of TSA and is one of the only two HDACIs approved by
the US Food and Drug Administration (FDA). SAHA is also currently
being evaluated in clinical trials for other tumors. As expected, SAHA
significantly reduces N-type cell viability in a dose-dependent manner,
whereas the SH-EP1 cells are less responsive to SAHA (Figure 2, bottom
panels). Interestingly, both SH-SY5Y cells and SH-EP1 cells are not very
responsive to MS275 treatment compared with tubacin treatment,
which, like that of SAHA, reduces significantly SH-SY5Y cell viability
but has a modest effect on SH-EP1 cells. These results strongly indi-
cate that HDAC6 may be involved in HDACI-induced cell viability in
NB cells.
To confirm that HDAC6 is playing a role in tubacin-induced cell
death, we knocked down HDAC6 in SH-SY5Y cells using HDAC6-
specific siRNA. Figure 3A shows that we have successfully knocked
down HDAC6 in SH-SY5Y cells without affecting the level of other
HDACs. More importantly, we have shown that knocking down
HDAC6 in SH-SY5Y cells reduces the viability of these cells (Fig-
ure 3B). As controls, we also knocked down HDAC1, 2, or 3 individ-
ually (Figure 3C ); blocking the activity of these enzymes with MS275
had not altered the cell’s viability previously (Figure 2, middle panels).
Indeed, we found that reducing the levels of these HDACs does
Figure 4. Treatment of SH-SY5Y cells with tubacin results in Ku70 acetylation, which is blocked by Ku70 K539/542R mutant. (A) Whole-
cell SH-SY5Y extracts were immunoprecipitated with either Bax or Ku70 antibody. The immunocomplexes were separated by SDS-PAGE
blotted for Ku70, Bax, or HDAC6. Normal rabbit serum and goat serum were used as immunoprecipitation controls. (B) SH-SY5Y cells
were treated with 1 μM TSA, 10 μM tubacin, or vehicle for 24 hours as shown. Lysates were immunoprecipitated using acetyl lysine
K103 antibody. The immune complexes were separated by SDS-PAGE and blotted for Ku70. (C) SH-SY5Y cells were transfected with
Flag-Ku70 WT or Flag-Ku70 (K539/542R) mutant. Twenty-four hours later, the cells were treated with either 10 μM tubacin or vehicle.
Lysates were prepared 24 hours after treatment and then immunoprecipitated with Bax antibodies. The immunocomplexes were then
blotted for either Flag (for Flag-Ku70s) or Bax antibodies. Normal rabbit serumwas used a control. (D) Cell viability of experiments shown in C
was measured by trypan blue exclusion assay. Results are expressed as mean ± SD (n = 3) of percent of control (Ku70 WT). The P value
of the significant difference between tubacin-treated Flag-Ku70 Wt transfected and Flag-Ku70 transfected alone was .012.
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not affect the cell’s viability either (Figure 3D). Together, these re-
sults strongly suggest that HDAC6 in SH-SY5Y cells regulates a cell
death mechanism.
HDAC6 Binds Ku70 and Bax and Inhibiting HDAC6
Increases Ku70 Acetylation
We reasoned that if HDAC6 regulates Ku70 acetylation, HDAC6
should complex with Ku70 and Bax. Indeed, in immunoprecipitation
assays using either Bax-specific antibody or Ku70-specific antibody,
we have shown that HDAC6 interacts with both Bax and Ku70
(Figure 4A). Furthermore, in immunoprecipitation assays using a
pan-anti–acetyl-lysine antibody (K103) and then probing with Ku70-
specific antibody, either tubacin or TSA treatment induced Ku70 acet-
ylation (Figure 4B). Tubacin treatment also releases Bax from Ku70
(Figure 4C ; compare lane 6 to lane 5 from the left) that is consistent
with our previous finding using TSA [4,5]. The release of Bax from
Ku70 after tubacin treatment can be rescued by overexpressing the
Ku70 acetylation mutant (K539R/K542R). This mutant has been
shown to rescue the TSA-induced cell death in NB cells [5]. This mutant
also reverses the reduced cell viability induced by tubacin treatment
(Figure 4D). Collectively, these results show that, in SH-SY5Y cells,
HDAC6 inhibits Ku70 acetylation, and inhibition of HDAC6 increases
Ku70 acetylation, triggering the release of Bax, resulting in Bax-dependent
cell death.
HDAC6 Expression Blocks CBP-Induced Cell Death
in SH-EP1 Cells
We have shown previously that S-type SH-EP1 cells are less respon-
sive to HDACI-induced killing [4]. The unresponsiveness to HDACI
inhibition is not due to the low level of Ku70 or Bax because we have
shown that Ku70 and Bax levels are comparable to those in SH-SY5Y
cells and that Ku70 and Bax form a complex in both cell types. One
mechanism of the unresponsiveness to HDAC inhibition in SH-EP1
cells might be the low levels of CBP because we have shown that over-
expressing CBP in these cells induces cell death and that this effect is
blocked by the Ku70 acetylation mutant (K539R/K542R). Another
possibility, suggested by our current findings, is that these cells have
low HDAC6 levels (Figure 1). We showed that further depletion of
HDAC6 level in these cells by HDAC6-specific siRNA did not affect
the level of other HDACs (Figure 5A); also, it did not alter the cell’s
viability (Figure 5B). To further test the role of HDAC6 in the regu-
lation of Ku70-Bax complex in these cells, we prepared SH-EP1 cells
stably expressing HDAC6 (Figure 5C ). We found that HDAC6 over-
expression in these cells blocks CBP-induced cell death (Figure 5D).
These results indicate that HDAC6 participates with CBP in regulating
the Ku70-Bax complex in SH-EP1 cells.
HDAC6 in NB Patient Samples
We have previously shown that the mediators of this proposed
HDACI-sensitive cell death pathway—Bax, Ku70, and CBP—are
Figure 5. Expressing HDAC6 rescues CBP-induced cell death in SH-EP1 cells. (A) SH-EP1 cells were transfected with scrambled siRNA
or HDAC6 siRNA. Mock transfection is used as a control. Cell lysates were prepared 48 hours after transfection and then immunoblotted
for HDACs as shown. β-Tubulin was used as a loading control. (B) Cell viability was measured using trypan blue exclusion assay. Results
are expressed as percent of control, mean ± SD, n = 3. (C) SH-EP1 stable cell lines expressing HDAC6-Flag or control vector were
transfected with CBP or the control vector. Twenty-four hours after transfection, the cells were lysed and then blotted for HDAC6,
Flag-tagged (for Flag-HDAC6), or CBP. β-Tubulin was used as a loading control. (D) Cell viability was measured using trypan blue exclu-
sion assay in experiment shown in C. Results are expressed as mean ± SD (n = 3) of percent of control.
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expressed in NB cell lines and primary tumors [4,5]. We therefore
sought to determine whether HDAC6 is also expressed in primary neu-
roblastic tumors. Normal adrenal medullae and all examined tumors
stained positively for HDAC6 by immunohistochemistry (Figure 6).
Nuclear expression of HDAC6 was modestly higher in the neuroblastic
component of malignant tumors (NB, 1.5; ganglioneuroblastoma, 1.6)
than in benign ganglioneuromas (1.0) and normal adrenal glands
(ND). However, there was a wide variability in staining patterns within
each group (Table 1). Cytoplasmic staining was more uniform and seen
in all specimen types.
Although nuclear HDAC6 protein expression was higher in biolog-
ically aggressive tumors, it is not yet known whether expression signif-
icantly correlates with clinical outcome. We expect that increased
expression of specific HDACs that deacetylate Ku70 would be required
for NB tumor survival and, thus, with worse patient outcome.We cannot
yet predict whether expression will be correlated with any single specific
prognostic marker; however, because the proposed mechanism by which
HDACs contribute to tumorigenesis is via increased genomic instability,
associations between HDAC expression and chromosomal changes or
MYCN amplification are expected. An association between HDAC6
expression and decreased patient survival would spur investigations into
clinical use of HDACIs for high-risk neuroblastic tumors. The absence of
a correlation between HDAC6 expression and outcome could mean that
an increased expression of HDAC6 is not required for aggressive behavior
and/or increased expression does not cause treatment failures on current
therapeutic regimens. The latter result would predict that treating pa-
tients with HDACIs would be of limited clinical utility.
Discussion
We have previously shown that HDAC inhibition using a broad
HDAC inhibitor (TSA) increases Ku70 acetylation, induces Bax
Figure 6. Immunohistochemical staining of primary neuroblastic tumors for HDAC6 protein. Normal adrenal medullae and all examined
tumors stained positively. Although there was wide variation in staining patterns, nuclear HDAC6 expression was modestly higher in the
neuroblastic component of malignant tumors; cytoplasmic staining was more uniform. (A) Normal adrenal gland. (B) Differentiating NB
with variable nuclear expression. (C) Poorly differentiated NB with strong nuclear expression. (D) Ganglioneuroblastoma (GNB) with
strong nuclear staining, and (E) GNB with weak nuclear staining.
Table 1. Distribution of HDAC6 Protein Expression in NB Tumor Tissue Arrays.
HDAC6 Protein Expression by IHC
Neuroblastic Component Stromal Component
0-1 1-2 2-3 0-1 1-2 2-3
NB 6 (24%) 9 (36%) 10 (40%) 1 (25%) 3 (75%) 0 (0%)
Ganglioneuroblastoma 1 (8.3%) 4 (33.3%) 7 (58.3%) 3 (50%) 3 (50%) 0 (0%)
Ganglioneuroma 0 (0%) 2 (40%) 3 (60%) 0 (0%) 2 (40%) 3 (60%)
Normal adrenal medulla 0 (0%) 1 (20%) 4 (80%) N/A N/A N/A
Immunohistochemistry (IHC) was performed using a commercially available polyclonal antibody
and tissue microarrays containing triplicate cores from each primary tumor (32 NBs, 10 intermixed
and nodular ganglioneuroblastomas, and 6 ganglioneuromas) and 5 normal adrenal glands. Each
tumor core was scored semiquantitatively as 0, 1+, 2+, or 3+; results reported in the table reflect
the mean for each tumor in each component across its three cores. The results are expressed as the
average staining for each tumor scoring as 0, 1, 2, or 3 and are reported as the mean from three
cores grouped by category of component (N- or S-) staining intensity (0-1, 1-2, or 2-3) and cat-
egory of tumor type (NB, ganglioneuroblastoma, ganglioneuroma, or normal adrenal gland). The
percentages under the categories are the percentage of tumors in a given category scoring with the
indicated intensity. Not all tumors had cores evaluable for both components; hence, numbers in
each table fall short of the overall tumor number.
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dissociation from Ku70, and triggers Bax-dependent cell death [4,5].
Although our results have indicated that CBP acetylates Ku70 in NB
cells, it is not clear which HDACs deacetylate cytosolic Ku70 to pro-
tect cells from Bax-induced death or nuclear Ku70. This must be es-
tablished to guide the selection of HDACIs to test this therapeutic
mechanism in NB treatment. Some recent studies have shown that
HDAC1 and HDAC8 are important in NB tumorigenesis [19,20],
which raises the possibility of their involvement and underscores
the importance of establishing which HDACs deacetylate Ku70 to
precisely target it therapeutically. Here, we provide evidence demon-
strating that HDAC6 forms a complex with cytoplasmic Ku70 and
that inhibition of HDAC6 activity, either by depleting endogenous
HDAC6 or by using HDAC6-specific inhibitors, increases Ku70
acetylation triggering Bax-dependent cell death. We have also shown
that HDAC6 is found in tumors from NB patients, underscoring the
potential importance of this HDAC as a therapeutic target in the
treatment of NB.
HDAC6 is a class IIb HDAC containing two catalytic domains
[21,22]. HDAC6 is mainly localized in the cytoplasm and has been
associated with many cell functions including tubulin stabilization,
cell motility, and regulation of the binding between Hsp90 and its
cochaperone [23]. A high level of HDAC6 has been associated with
ovarian cancer [24] and breast cancer [25], but it is unclear whether
HDAC6 plays a role in tumor development or tumor maintenance.
The role of HDAC6 in cell survival is highlighted by its involvement
in aggresome, an alternate pathway that regulates protein degradation
in cells. It has been shown that HDAC6 inhibitor enhances the effect of
proteosome inhibitor in killing cancer cells, resulting in the reduction of
cell viability, mainly because, when the proteosome pathway is blocked,
cells degrade unfolded proteins using the aggresome pathway, but if
both pathways are blocked, it will trigger cell death [26].
Although HDAC6 has been identified in complex isolated from var-
ious cellular contexts [27], three direct deacetylation substrates have
been reported, including tubulin [28], cortactin [29], and Hsp90
[30]. Our results show that Ku70 is another substrate of HDAC6.
Although we do not have direct in vitro evidence (using purified
HDAC6 and purified acetylated Ku70) showing that acetylated
Ku70 is a direct substrate of HDAC6, our results show that blocking
HDAC6 activity using tubacin increases Ku70 acetylation and that
tubacin treatment increases NB cell death, which is blocked by the
Ku70 deacetylation mutant. These results are consistent with our pro-
posed model in which Ku70 acetylation is regulated by HDAC6 and
that blocking HDAC6 activity will result in Ku70 acetylation triggering
Bax-dependent cell death.
We have shown previously that Ku70 is required for the survival
of some NB cells because knocking down of Ku70 by siRNA triggers
Bax-dependent cell death [4]. Thus, for the NB cells to survive,
Ku70 must be kept unacetylated. Currently, it is not clear how the
deacetylation activity of HDAC6 is regulated in cells. Although we have
shown that HDAC6 is expressed in NB tumor samples, its expression is
not correlated with any clinical outcome variables, such as stages or
patient survival. Much work is needed to elucidate how HDAC6 is
regulated in cells. This information may provide addition therapeutic
targets to suppress HDAC6 activity in cells.
Although currently there is no HDAC6-specific inhibitor approved
by the FDA or in clinical trials, recent development of more potent
and more specific HDAC6 inhibitors is encouraging [31,32]. Using
HDAC6-specific inhibitors in the treatment of NB is beneficial be-
cause it is not known whether simultaneous inhibition of class I and II
HDACs by current FDA-approvedHDAC inhibitor, SAHA, may have
other effects other than the specific targets.
Our results show the feasibility of targeting a single HDAC to thera-
peutically engage the Ku70-Bax complex in NB. Whether it is due to
differing HDAC expression or due to the overlap between HDAC ac-
tivities in processing Ku70 as a substrate in the cytoplasm or in the nu-
cleus will require more selective agents. Knowing the identity of the
deacetylases that deacetylate Ku70 in the cytoplasm is of fundamental
importance in understanding how Ku70 acetylation is regulated in NB.
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